Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Cyclopentanohydrophenanthrene ring system doai
Reexamination Certificate
2005-02-28
2010-10-12
Badio, Barbara P (Department: 1628)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Cyclopentanohydrophenanthrene ring system doai
C552S551000
Reexamination Certificate
active
07812011
ABSTRACT:
The invention relates to a FXR agonist of formula (I) and pharmaceutically acceptable salts, solvates or amino acid conjugates thereof.
REFERENCES:
patent: 0312867 (1989-04-01), None
patent: WO 03/080803 (2003-10-01), None
patent: WO 2004/007521 (2004-01-01), None
Souillac, et al., Characterization of Delivery Systems, Differential Scanning Calorimetry, pp. 217-218 (in Encyclopedia of Controlled Drug Delivery, 1999, John Wiley & Sons, pp. 212-227).
Vippagunta et al. (Advanced Drug Delivery Reviews, 48 (2001), pp. 3-26).
Li-Zhi Mi, et al. “Structural Basis for Bile Acid Binding and Activation of the Nuclear Receptor FXR”: Molecular Cell, vol. 11, 2003; pp. 1093-1100.
R. Pellicciari, et al. “6a-Ethyl-Chenodeoxycholic Acid (6-ECDCA), a Potent and Selective FXR Agonist Endowed with Anticholestatic Activity”, Journal of Medicinal Chemistry, vol. 45, No. 17; Aug. 15, 2002; pp. 3569-3572.
International Search Report dated Aug. 31, 2005 for PCT/EP2005/002086.
Badio Barbara P
Elrifi Ivor R.
Intercept Pharmaceuticals, Inc.
Loebach Jennifer
Mintz Levin Cohn Ferris Glovsky and Popeo P.C.
LandOfFree
Steroid agonist for FXR does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Steroid agonist for FXR, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Steroid agonist for FXR will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4187325